A Study of HC006 in Subjects With Advanced Solid Tumors - Trial NCT06304571
Access comprehensive clinical trial information for NCT06304571 through Pure Global AI's free database. This Phase 1 trial is sponsored by HC Biopharma Inc. and is currently Recruiting. The study focuses on Advanced Solid Tumor. Target enrollment is 76 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
HC Biopharma Inc.
Timeline & Enrollment
Phase 1
Feb 27, 2024
Jul 16, 2026
Primary Outcome
Incidence of Dose Limiting Toxicities(DLTs),Incidence of adverse events(AEs),Incidence of Serious adverse events(SAEs),Clinically Significant changes in safety assessments
Summary
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics (PK),
 Immunogenicity and preliminary antitumor activity of HC006 in subjects with advanced solid
 tumor malignancies. This study is a first-in-human (FIH) study of HC006 in subjects with
 advanced solid tumors.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06304571
Non-Device Trial